AstraZeneca (LON:AZN – Get Free Report) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft to a “hold” rating in a research note issued to investors on Monday, Digital Look reports.
A number of other equities research analysts have also recently issued reports on AZN. Berenberg Bank reiterated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, March 13th. BMO Capital Markets reiterated an “outperform” rating on shares of AstraZeneca in a research note on Monday, February 12th. Jefferies Financial Group reiterated a “hold” rating and set a £110 ($136.94) price objective on shares of AstraZeneca in a research note on Friday, February 16th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Monday. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, April 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of £115.43 ($143.69).
Check Out Our Latest Analysis on AstraZeneca
AstraZeneca Price Performance
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- Trading Halts Explained
- ASML Fires Warning Shot For Tech Investors
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Prologis Stock Leading U.S. Logistics Boom
- Financial Services Stocks Investing
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.